首页 » 文章 » 文章详细信息
Cardiology Research and Practice Volume 2019 ,2019-07-17
A Systems-Based Analysis of the CardioMEMS HF Sensor for Chronic Heart Failure Management
Research Article
Jeffrey S. Tran 1 Aaron M. Wolfson 2 Daniel O’Brien 3 Omid Yousefian 1 David M. Shavelle 2
Show affiliations
DOI:10.1155/2019/7979830
Received 2019-01-20, accepted for publication 2019-06-12, Published 2019-06-12
PDF
摘要

Background. Hemodynamic-guided therapy using the CardioMEMS™ system has been shown to reduce heart failure hospitalization (HFH) in both clinical trials and real-world settings. However, the CardioMEMS system requires input from multiple independent elements to achieve its effect, and no studies have been done to investigate those elements. Consistent patient participation and health care provider participation are two of those key elements, and this study sought to assess how they affect HFHs. Methods. This was a single-center, retrospective cohort study of patients with the CardioMEMS sensor. The primary outcome was the number of HFH days patients experienced in the 1 year following CardioMEMS sensor implant. The primary independent variables were the average number of days between patient transmissions of data and the average number of days between health care provider reviews of those data. Covariates included patient demographics, medical comorbidities, history of HFHs, and initial pressure response to hemodynamic-guided therapy at 28 days after implant. Data were fit to a zero-inflated negative binomial regression. Results. Seventy-eight patients were included in the study. The mean age was 64 ± 15 years, 52 (67%) were male, and 58 (76%) had heart failure with reduced ejection fraction. During the study period, there were 538 cumulative HFH patient-days. Based on the regression model, there was an exponential relationship between HFH days and the mean number of days between patient transmissions (IRR = 1.74, 95% CI: 1.09–2.75, p=0.019). There was also an exponential relationship between HFH days and the mean number of days between health care provider reviews (IRR = 1.03, 95% CI: 1.01–1.05, p=0.013). Conclusions. This single-center study suggests that more frequent patient transmissions and health care provider reviews of the CardioMEMS system are associated with a decreased number of HFH days, but larger multicentered studies are required. Further systems-based analyses of the CardioMEMS system may be a useful approach to guiding effective use of the CardioMEMS device.

授权许可

Copyright © 2019 Jeffrey S. Tran et al. 2019
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

通讯作者

Jeffrey S. Tran.Department of Internal Medicine, Keck School of Medicine of USC, Los Angeles 90033, CA, USA, usc.edu.jstchen01@gmail.com

推荐引用方式

Jeffrey S. Tran,Aaron M. Wolfson,Daniel O’Brien,Omid Yousefian,David M. Shavelle. A Systems-Based Analysis of the CardioMEMS HF Sensor for Chronic Heart Failure Management. Cardiology Research and Practice ,Vol.2019(2019)

您觉得这篇文章对您有帮助吗?
分享和收藏
0

是否收藏?

参考文献
[1] P. A. Heidenreich, N. M. Albert, L. A. Allen. (2013). Forecasting the impact of heart failure in the United States: a policy statement from the American heart association. Circulation: Heart Failure.6(3):606-619. DOI: 10.1161/CIR.0000000000000152.
[2] W. Zareba, J. S. Steinberg, S. McNitt, J. P. Daubert. et al.(2006). Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. Heart Rhythm.3(6):631-637. DOI: 10.1161/CIR.0000000000000152.
[3] M. S. Maurer, P. B. Adamson, M. R. Costanzo. (2015). Rationale and design of the left atrial pressure monitoring to optimize heart failure therapy study (LAPTOP-HF). Journal of Cardiac Failure.21(6):479-488. DOI: 10.1161/CIR.0000000000000152.
[4] W. T. Abraham, L. W. Stevenson, R. C. Bourge, J. A. Lindenfeld. et al.(2016). Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomized trial. The Lancet.387(10017):453-461. DOI: 10.1161/CIR.0000000000000152.
[5] M. A. Mamas, J. C. Caldwell, S. Chacko, C. J. Garratt. et al.(2009). A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. European Journal of Heart Failure.11(7):676-683. DOI: 10.1161/CIR.0000000000000152.
[6] S. M. Dunlay, N. D. Shah, Q. Shi. (2011). Lifetime costs of medical care after heart failure diagnosis. Circulation: Cardiovascular Quality and Outcomes.4(1):68-75. DOI: 10.1161/CIR.0000000000000152.
[7] P. B. Adamson, M. R. Gold, T. Bennett. (2011). Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of the reducing decompensation events utilizing intracardiac pressures in patients with chronic heart failure (REDUCEhf) trial. Congestive Heart Failure.17(5):248-254. DOI: 10.1161/CIR.0000000000000152.
[8] A. S. Desai, A. Bhimaraj, R. Bharmi. (2017). Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in “real-world” clinical practice. Journal of the American College of Cardiology.69(19):2357-2365. DOI: 10.1161/CIR.0000000000000152.
[9] R. Jermyn, A. Alam, J. Kvasic, O. Saeed. et al.(2017). Hemodynamic-guided heart-failure management using a wireless implantable sensor: infrastructure, methods, and results in a community heart failure disease-management program. Clinical Cardiology.40(3):170-176. DOI: 10.1161/CIR.0000000000000152.
[10] L. Di Base, P. Mohanty, S. Mohanty. (2016). Ablation vs. amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation.133(17):1637-1644. DOI: 10.1161/CIR.0000000000000152.
[11] P. B. Adamson, M. R. Zile, Y. K. Cho. (2011). Hemodynamic factors associated with acute decompensated heart failure: part 2-use in automated detection. Journal of Cardiac Failure.17(5):366-373. DOI: 10.1161/CIR.0000000000000152.
[12] N. F. Marrouche, J. Brachmann, D. Andresen. (2018). Catheter ablation for atrial fibrillation with heart failure. New England Journal of Medicine.378(5):417-427. DOI: 10.1161/CIR.0000000000000152.
[13] J. Ritzema, R. Troughton, I. Melton. (2010). Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation.121(9):1086-1095. DOI: 10.1161/CIR.0000000000000152.
[14] C. A. Lawson, P. W. Jones, L. Teece. (2018). Association between type 2 diabetes and all-cause hospitalization and mortality in the UK general heart failure population. JACC: Heart Failure.6(1):18-26. DOI: 10.1161/CIR.0000000000000152.
[15] D. Mozaffarian, E. J. Benjamin, A. S. Go. (2015). Heart disease and stroke statistics—2015 update: a report from the American heart association. Circulation.131(4):e29-e322. DOI: 10.1161/CIR.0000000000000152.
[16] R. C. Bourge, W. T. Abraham, P. B. Adamson. (2008). Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure. Journal of the American College of Cardiology.51(11):1073-1079. DOI: 10.1161/CIR.0000000000000152.
[17] M. R. Zile, P. B. Adamson, Y. K. Cho. (2011). Hemodynamic factors associated with acute decompensated heart failure: part 1-insights into pathophysiology. Journal of Cardiac Failure.17(4):282-291. DOI: 10.1161/CIR.0000000000000152.
[18] J. T. Heywood, R. Jermyn, D. Shavelle. (2017). Impact of practice-based management of pulmonary artery pressures in 2000 patients implanted with the CardioMEMS sensor. Circulation.135(16):1509-1517. DOI: 10.1161/CIR.0000000000000152.
文献评价指标
浏览 4次
下载全文 0次
评分次数 0次
用户评分 0.0分
分享 0次